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Background: Degenerative aortic valve (AV) stenosis is the most prevalent heart valve disease in the western world.
Surgical aortic valve replacement (SAVR) has until recently been the standard of treatment for patients with severe
AV stenosis. Whether transcatheter aortic valve implantation (TAVI) can be offered with improved safety and similar
effectiveness in a population including low-risk patients has yet to be examined in a randomised setting.
Methods/Design: This randomised clinical trial will evaluate the benefits and risks of TAVI using the transarterial
CoreValve System (Medtronic Inc., Minneapolis, MN, USA) (intervention group) compared with SAVR (control group)
in patients with severe degenerative AV stenosis. Randomisation ratio is 1:1, enrolling a total of 280 patients aged
70 years or older without significant coronary artery disease and with a low, moderate, or high surgical risk profile.
Trial outcomes include a primary composite outcome of myocardial infarction, stroke, or all-cause mortality within
the first year after intervention (expected rates 5% for TAVI, 15% for SAVR). Exploratory safety outcomes include
procedure complications, valve re-intervention, and cardiovascular death, as well as cardiac, cerebral, pulmonary,
renal, and vascular complications. Exploratory efficacy outcomes include New York Heart Association functional
status, quality of life, and valve prosthesis and cardiac performance. Enrolment began in December 2009, and 269
patients have been enrolled up to December 2012.
Discussion: The trial is designed to evaluate the performance of TAVI in comparison with SAVR. The trial results
may influence the choice of treatment modality for patients with severe degenerative AV stenosis.
Trial registration: ClinicalTrials.gov: NCT01057173
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Degenerative aortic valve (AV) stenosis is the most
prevalent heart valve disease in the western world,
affecting 2 to 7% of people older than 65 years of age.
Both the incidence and prevalence are expected to rise
due to the general increase in life expectancy [1,2]. The
disease has a chronic course and carries a poor progno-
sis after onset of symptoms [3]. Medical therapy offers
sparse symptomatic relief, and symptomatic patients
have a 2-year survival of approximately 50%. Surgical
aortic valve replacement (SAVR) is an effective treat-
ment, and complication rates and prosthesis durability
are well known. The surgical procedure carries a low op-
erative risk in younger patients without any significant
co-morbidity (30-day mortality 3 to 5% for age <70
years). This risk increases substantially with increasing
age, reduced left ventricular function, and other co-
morbidities (30-day mortality 5 to 15%) [4,5]. Presum-
ably because of this increase, almost one-third of
patients referred for valve intervention at the time of
trial design did not receive valve replacement and were
continued on medical therapy [6]. A less invasive treat-
ment option would therefore be attractive.
Different operative risk calculators in cardiac surgery
(the Society of Thoracic Surgery Predicted Risk of Mor-
tality (STS) score [7] and the European System for Car-
diac Operative Risk Evaluation (EuroSCORE) [8]) have
been developed to identify the high-risk surgical patient,
but these are inadequate and generally overestimate the
operative mortality in SAVR. A new EuroSCORE II has
been developed and is being considered for implementa-
tion [9]. Data from randomised clinical trials are needed
to improve treatment decision-making.
In recent years a new treatment option has become
available for patients considered at high risk for SAVR.
Transcatheter aortic valve implantation (TAVI) was ori-
ginally developed in 1992 by Andersen and coworkers
and was clinically introduced in 2002 by Cribier and
coworkers as a minimally invasive treatment for patients
considered ineligible for valve surgery [10,11]. The term
TAVI comprises different valve prosthesis types, techni-
ques, and approaches to the stenosed valve. Originally
developed as a transvenous transseptal septal technique,
the procedure is currently performed on the beating
heart either antegrade transapically through a small left
anterior thoracotomy or retrograde through the arterial
system using either the femoral, subclavian, or carotid
artery, or with the direct transaortic approach [12,13].
The artery can be surgically exposed or punctured. The
two most widely used TAVI systems, both Conformité
Européenne (European Conformity) marked, are the
Edwards SAPIEN with a balloon-expandable bioprosth-
esis (Edwards Lifescience Inc., Irvine, CA, USA) and the
CoreValve System with a self-expandable bioprosthesis(Medtronic Inc., Minneapolis, MN, USA). The former
has also been Food and Drug Administration approved
in the United States.
Postoperative complications related to SAVR stem
from sternotomy, cardiopulmonary bypass, aortic cross-
clamping, and cardioplegic cardiac arrest. In TAVI many
of the SAVR complications are potentially avoided, but
others are potentially exacerbated such as neurological
lesions (2 to 11% during the first year) [14,15]. Retro-
grade catheter passage in the aortic arch and ascending
aorta, and native valve pre-dilatation – causing calcified
and often ulcerated leaflets to fracture, exposing
thrombogenic endothelial lesions to the circulation –
could generate atherosclerotic emboli. At the same time,
TAVI-specific complications have been encountered –
including haemodynamic instability and arrhythmia
during implantation, prosthesis misplacement, and incom-
plete frame expansion (leading to prosthesis embolisation,
valvular and paravalvular leakage, and valve-in-valve im-
plantation, or conversion to open surgery), aortic and ven-
tricular perforations, and arterial access lesions [16].
Furthermore, the CoreValve System has a high frequency
of conduction abnormalities (atrioventricular and left bun-
dle branch block) requiring a permanent pacemaker in 20
to 30% of patients, presumably because of septal compres-
sion [17]. Since operator experience has grown and im-
plantation systems have improved and become smaller,
many of these complications have become less frequent.
National and international registries have documented
good short-term and mid-term safety results after TAVI
in patients considered at high risk for surgery with a
95% procedure success rate, and with 30-day mortality,
stroke, and myocardial infarction rates of 5 to 12%, 2 to
10%, and 1 to 4%, respectively, combined with excellent
sustained prosthesis function, and clinical improvements
[15,16,18-20]. Long-term results are lacking, but no
reports of fractured prosthetic stents or frames have
been published. Anecdotal reports of calcified TAVI
prostheses after 5 years have been published [21].
Results after 1 and 2 years from the randomised trial
(PARTNER Trial) comparing the Edwards SAPIEN pros-
thesis with standard medical therapy in patients consid-
ered to have prohibitive high surgical risk (Cohort B),
and with SAVR in patients with high surgical risk (Co-
hort A) have been published [22-25]. For Cohort B an
all-cause mortality reduction within the first year of 20%
was observed (TAVI vs. medical therapy, 30.7% vs.
50.7%; P <0.001), and for Cohort A non-inferiority for
all-cause death after 1 year was proven (TAVI vs. SAVR,
24.2% vs. 26.8%; P = 0.44). Complication rates were sig-
nificantly different, with more strokes and vascular injur-
ies in the TAVI group but more major bleedings and
more new-onset atrial fibrillation in the SAVR group.
Another randomised trial using the Edwards SAPIEN
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This trial was prematurely terminated after including 70
patients because of a nonsignificant excess of events in
the TAVI group [26].
No randomised trials comparing TAVI versus SAVR in
patients with low, moderate, and high operative risk and
using the CoreValve System have been reported. Typic-
ally, high-risk patients considered for TAVI in current
clinical practice have a logistic EuroSCORE >20% and
STS score >10% predicted 30-day operative mortality.
Low-risk patients could have a logistic EuroSCORE of
3% and a STS score of 1%. Patient preferences, the less
invasive technique, and unclear indications could pro-
mote off-label use of TAVI, as has been seen in percu-
taneous coronary intervention. A randomised clinical
trial can examine this new treatment option more exten-
sively and generate evidence needed to broaden, opti-
mise, and guide treatment for patients with severe
degenerative AV stenosis [27].
Methods/Design
Trial design and objectives
The Nordic Aortic Valve Intervention (NOTION) trial is
a multicentre, randomised clinical trial without blinding
comparing TAVI using the CoreValve System versus
SAVR in the treatment of severe AV stenosis designed
during 2008/09 and launched in December 2009. The
primary objective is to evaluate the safety and effective-
ness of TAVI using the CoreValve System compared with
SAVR using cardiopulmonary bypass.
The regional ethics committee has approved the trial at
each clinical site, and all patients will provide written
informed consent. The trial is conducted according to the
Declaration of Helsinki. The organisational and coordinat-
ing site is The Heart Centre, Rigshospitalet, Copenhagen
University Hospital, Copenhagen, Denmark, and the re-
gional Research Ethics Committee in The Capital Region
of Denmark approved the protocol. Other clinical sites
are Odense University Hospital, Odense, Denmark, and
Sahlgrenska University Hospital, Gothenburg, Sweden. The
trial is registered at ClinicalTrials.gov (NCT01057173).
The trial is investigator initiated, designed, and con-
ducted with no sponsor involvement. The trial has a
steering committee, an independent event adjudication
committee, and an external independent data monitor-
ing and safety committee (DMSC). The DMSC is com-
posed of an interventional cardiologist, a cardiac
surgeon, a neurologist, and a statistician.
Device and procedures
The CoreValve System is a TAVI system designed to
treat AV stenosis [20]. The procedure can be done on
the beating heart with a retrograde arterial access. Thethird-generation system used for this trial includes a
valve bioprosthesis consisting of a porcine pericardial
trileaflet valve mounted in a nitinol self-expandable
frame (frame diameter size 23, 26, 29, or 31 mm cover-
ing an aortic annulus diameter from 18 to 29 mm,
length 52 to 55 mm; Figure 1), and an 18 French (6
mm) delivery system that enables implantation of the
prosthesis. The TAVI procedure is performed under
local or general anaesthesia in the cardiac catheterisation
laboratory, either percutaneously via the femoral artery
or after surgical cut-down of the subclavian artery. Be-
fore implantation, the native AV is pre-dilated with a
balloon valvulotomy during rapid ventricular pacing to
ensure a stable position of the balloon. The prosthesis is
crimped in the delivery catheter. During deployment,
the prosthetic frame will expand to its preformed shape
and lodge itself in the left ventricular outflow tract, the
aortic annulus, and the ascending aorta. The prosthesis
can be retrieved until fully deployed, and an intervention
catheter can pass through the frame to the coronary
ostia. The access vessel is closed either with a percutan-
eous suture system (ProStar XL or Perclose ProGlide;
Abbott Vascular, Inc., Menlo Park, CA, USA) or surgi-
cally. Before implantation a temporary pacemaker lead is
placed in the right ventricle, used for rapid pacing and
in case of conduction abnormalities. Correct prosthesis
placement during and after deployment is verified by
fluoroscopy and echocardiography. Before the proced-
ure, patients receive a loading dose of 300 mg clopido-
grel. During the procedure, intravenous antibiotics are
given before skin puncture, and 5,000 units heparin are
given after vascular access has been established. After
the procedure, patients receive 75 mg clopidogrel daily
for 3 months as well as 75 mg acetyl salicylic acid life-
long. If vitamin K antagonist therapy is indicated, this is
added to the above treatment. Other cardiac medications
are prescribed according to local cardiologic guidelines.
SAVR is performed using standard surgical techniques
and general anaesthesia. The procedure includes a
complete median sternotomy, cardiopulmonary bypass
in normothermia, aortic cross-clamping, and cold blood
cardioplegic cardiac arrest. The native valve is excised
and the annulus is carefully decalcified and irrigated be-
fore a bioprosthesis is sutured in place. The choice of
type and size of the prosthesis is at the discretion of the
surgeon. Radiofrequency ablation will be performed for
chronic or intermittent atrial fibrillation. Postoperative
antiplatelet and other cardiac medical therapy is similar
to the TAVI group.
After the procedure, both patient groups will be ad-
mitted to a specialised cardiac intensive care unit at least
overnight, and TAVI patients will thereafter be trans-
ferred to the cardiology ward and SAVR patients to the
cardiac surgery ward.
Figure 1 The transcatheter aortic valve implantation bioprosthesis. The third-generation porcine pericardial trileaflet valve mounted in a
self-expanding nitinol support frame (CoreValve System; Medtronic Inc., Minneapolis, MN, USA). TAVI, transcatheter aortic valve implantation.
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Eligible patients include those aged 70 years or older
with severe degenerative AV stenosis with symptoms or
without symptoms but with left ventricular systolic dys-
function and/or hypertrophy (see Table 1 for all inclu-
sion and exclusion criteria). Patients must be suitable for
both TAVI and SAVR according to a cardiac surgeon, an
interventionist, and an echocardiographer at a multidis-
ciplinary conference. Inclusion criteria follow general
surgical indications and the TAVI system manufacturer’s
guidelines for severe AV stenosis. Patients with previous
heart surgery, other significant valve disease, or coronary
artery disease requiring revascularisation at the time of
referral are excluded. Patients with a stroke or transient
ischemic attack within the previous 30 days or an acute
coronary syndrome within the previous year are also
excluded.
Patient screening, randomisation, and follow-up
All patients consecutively referred for SAVR at each
study centre (all tertiary university hospitals) have been
screened since December 2009 for eligibility at a multi-
disciplinary conference (Figure 2). Patients determined
as ineligible are recorded for registries and follow-up.
Potential eligible patients are interviewed and informed
of trial risks and objectives before obtaining informed
consent. Transthoracic echocardiography (transoesopha-
geal studies are done if appropriate), coronary, aortic,
and femoro-iliac angiograms, lung function tests, and
standard laboratory blood samples are obtained in order
to determine eligibility. Electrocardiogram (ECG)-gated
high-resolution computed tomography studies can be
used to evaluate the aortic annulus and root, and non-
ECG-gated studies can further evaluate the arterial
system.
The trial will be conducted at three sites in Scandi-
navia and will enrol up to 280 patients. Randomisation
will be 1:1 with approximately 140 patients in eachgroup (TAVI and SAVR) and stratified according to age
(70 to 74 years or ≥75 years), coronary status (coronary
artery disease not requiring revascularisation or normal),
and trial site. Randomisation is central at the Copenhagen
Trial Unit, which has generated the allocation sequence
in permuted blocks with unknown block size for the
investigators.
Patients undergo the assigned treatment with either
TAVI using the CoreValve System or SAVR. Clinical
follow-up with outcome measure recording, blood sam-
ples, and ECG occurs at pre-discharge and at 1, 3, 6, 12
months, and annually for a minimum of 5 years. Trans-
thoracic echocardiography studies are performed before
discharge and after 3 and 12 months, and annually.
Patients will furthermore be followed in external elec-
tronic medical records and retrieved medical records for
hospital admissions, the Danish National Hospital Regis-
try [28], the Civil Registration System [29], and the
Registry of Causes of Death [30].
Outcomes
The primary outcome is the composite of myocardial in-
farction, stroke, or all-cause mortality within the first 12
months (Table 2). Formal neurological evaluations and
computed tomography cerebral studies will only be per-
formed when clinically indicated and not routinely. ECGs
and coronary markers will be evaluated routinely the first
3 days after the intervention and when indicated.
Exploratory safety outcomes at 30 days and 12 months
include all-cause mortality; cardiovascular mortality;
cardiac and prosthetic AV complications (myocardial in-
farction; new-onset arrhythmias and conduction abnor-
malities; prosthetic AV re-intervention, and endocarditis);
stroke (ischaemic and haemorrhagic). Exploratory safety
outcomes at 30 days include pulmonary, renal, access-
related vascular and bleeding complications. Exploratory
safety outcomes at 12 months include number of days
hospitalised.
Table 1 Inclusion and exclusion criteria
Inclusion criteria
• Severe degenerative AV stenosis (calcified AV, effective orifice area <1
cm2 or indexed for body surface area <0.6 cm2/m2, mean AV
gradient >40 mmHg, or AV peak systolic velocity >4.0 m/second),
and
• Symptomatic (dyspnoea ≥NYHA class II, angina pectoris, or syncope),
or
• Asymptomatic with one or more of the following:
• Left ventricle posterior wall thickness ≥17 mm
• Left ventricular ejection fraction <60% but ≥20%
• Atrial fibrillation
• Age ≥70 years
• Candidate (clinical and anatomical) for both TAVI and SAVR (as
specified by prosthesis manufacture’s guidelines) judged by a
multidisciplinary conference
• Expected to survive ≥1 year after intervention
• Able to provide written informed consent
Exclusion criteria
• Isolated AV insufficiency
• Other significant cardiac valve or septal diseases
• Coronary artery comorbidity requiring revascularisation (PCI or CABG)
• Intracardiac lesion (thrombus, tumour, vegetation)
• Previous open cardiac surgery
• Myocardial infarction or PCI within the last year
• Stroke or transient ischemic attack within the last 30 days
• Renal insufficiency requiring haemodialysis
• Pulmonary insufficiency (FEV1 or diffusion capacity <40% of
expected)
• Active infectious disease requiring antibiotics
• Emergency intervention (within 24 hours after the indication for
intervention has been made)
• Unstable pre-interventional condition requiring inotropic support or
mechanical cardiac assistance
• A known hypersensitivity or contraindication to nitinol, heparin,
clopidogrel, acetyl salicylic acid, or contrast material
• Currently participating in an investigational drug or another device
study
AV, aortic valve; CABG, coronary artery bypass grafting; FEV1, forced expiratory
volume in 1 second; NYHA, New York Heart Association; PCI, percutaneous
coronary intervention; SAVR, surgical aortic valve replacement; TAVI,
transcatheter aortic valve implantation.
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formance outcomes at 3 and 12 months include New
York Heart Association functional class, quality of life
(Short-form health survey with 36 questions question-
naire), and prosthetic AV opening area, peak and mean
pressure gradients, prosthetic–patient mismatch, and re-
gurgitation, as well as left ventricular function.
All outcomes will be assessed and recorded before dis-
charge and at all follow-up visits.Definitions of outcomes are adopted from the gener-
ally accepted Valve Academic Research Consortium con-
sensus report for TAVI clinical trials [31,32].
Evaluation of the primary outcome measure by the in-
dependent event adjudication committee will be blinded
to the intervention performed. The blinding consists of
removal of all information related to the type of inter-
vention and prosthesis from collected patient records.
The evaluation of exploratory outcomes, except for qual-
ity of life data, is difficult to blind since procedure and
prosthesis types can be identified.
All required trial data and outcomes will be collected
on standardised patient report forms and transferred to
a central database for storage. The principal investigators
at the organising trial site will manage and prepare data
for publication, and an external independent statistician
will perform the statistical analysis.
Sample size calculation
The trial is designed as a randomised superiority trial
with the alternative hypothesis that TAVI is better than
SAVR regarding the effect on the primary composite
outcome consisting of myocardial infarction, stroke, or
all-cause mortality after 1 year of follow-up. As the pri-
mary outcome measure is a binary variable, the sample
size may be estimated using a chi-square test with one
degree of freedom and an equal number of patients in
each treatment group. Based on the estimated occur-
rence of the primary outcome measure of 15% in the
SAVR group and 5% in the TAVI group during the first
year, corresponding to an absolute risk reduction of 10%
or a relative risk reduction of 66.7%, and a chosen power
of 1 – β = 80% and two-sided α = 5%, then 280 patients
(140 patients per intervention group) are needed.
Statistical analysis plan
All analyses will be intention-to-treat analyses performed
blinded with two-sided tests and 5% level of significance.
Table 2 shows for each outcome its priority (primary or
to be used for explorative analyses), the time at which or
the period during which it will be measured, the type of
variable, and the analytical procedure (see below) to be
used.
Analytical procedures
Depending on type of outcome measure, one of four
types of regression analyses will be applied. The primary
analytical results are those adjusted for age, trial site,
presence of coronary disease not requiring revascularisa-
tion, and baseline value (possibly following multiple
imputations; see below). Unadjusted analyses will also be
carried out and major discrepancies between the results
of adjusted and unadjusted analyses will be discussed.
The types of regression analyses are as follows.
Figure 2 Study flow chart. An allcomers trial design. SAVR, surgical aortic valve replacement; TAVI, transcatheter aortic valve implantation.
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gence fit or non-estimable odds ratios, Fisher’s exact test
will be used and the protocol specified covariates thus
disregarded.
Type 2: Includes a count of events within a specified
period (12 months). Using the countreg procedure (SAS
software version 9.3, SAS Institute Inc., Cary, NC, USA),
the Poisson model, the negative binomial model, the zero
inflated Poisson model, and the zero inflated negative bino-
mial model will be compared by testing for overdispersion
and comparing the average predicted count probabilities
and the observed proportions. The best model will be used
to analyse the count data. As a sensitivity analysis, a non-
parametric test (Mann–Whitney test) will be conducted to
compare the distributions of counts between the groups
and the results will be discussed.
Type 3: Regression analysis using the proportional
odds model for ordered variables. If the model assump-
tion is significantly violated, then the Mann–Whitney
test will be used.
Type 4: The general linear univariate model will be used.
As a sensitivity analysis, a nonparametric test (Mann–
Whitney test) will be conducted and the results discussed.
An explorative time-to-event analysis based on all
available follow-up data on mortality will be conducted
using Kaplan–Meier estimates and comparisons between
groups with the use of the log-rank test.Missing values
If the missingness exceeds 5% or the result of Little’s test
is significant (P <0.05), then multiple imputations will be
used (SPSS software version 17 or later, IBM Corp.,
Armonk, NY, USA). Ten imputed datasets will be gener-
ated and used.The potential for bias caused by values missing not at
random will be assessed for the primary outcome as a
sensitivity analysis as follows: let A be the group with a
beneficial effect of intervention as compared with the
other group B. The missing values in A will be imputed
by 1 (signifying that an event occurred) and those in
group B by 0.Multiplicity
All outcomes apart from the primary outcome measure
are exploratory and hypothesis generating.
The DMSC will conduct an interim analysis after the
first 20 primary outcomes have occurred, which may
prompt the DMSC to advise the steering committee to
terminate or modify the trial if a significant difference is
likely. The interim analyses are based on a statistical ap-
proach defined in the charter for the work of the DMSC.
A random sample of 10% of patients will have their data
monitored with source data verification by the regional
good clinical practice unit. All statistical analysis will be
performed with the use of SPSS or SAS software.Discussion
The design of the NOTION trial is unique in that no ran-
domised comparisons have been made between TAVI with
the CoreValve System versus SAVR in a cohort of low-
risk, moderate-risk, and high-risk patients. The trial is
designed to determine whether TAVI is safer than SAVR
with similar efficacy in reducing AV stenosis. Favourable
TAVI registry data are expanding, but randomised data
are lacking. Despite this and high treatment costs, the
number of TAVI procedures is increasing rapidly.
Designing a trial comparing TAVI versus SAVR is
challenging. Complication types and their rates following
Table 2 Outcomes, variable type, time/period of measurement, and statistical analysis for primary and exploratory
outcomes
Outcomea Type of variable Time or period of measurement Statistical type of analysisb
Myocardial infarction, stroke, or all-cause mortality (P) Binary During 12 months 1
Myocardial infarction (E) Binary During 30 days. During 12 months 1
Stroke (E) Binary During 30 days. During 12 months 1
All-cause mortality (E) Binary During 30 days. During 12 months 1
Cardiovascular mortality (E) Binary During 30 days. During 12 months 1
Prosthesis re-intervention (E) Binary During 30 days. During 12 months 1
Conduction abnormality requiring pacemaker (E) Binary During 30 days. During 12 months 1
Arrhythmia (E) Binary During 30 days. During 12 months 1
Endocarditis (E) Binary During 30 days. During 12 months 1
Mechanical ventilation in ≥24 hours (E) Binary During 30 days 1
Acute kidney injury (stage 2 or 3) (E) Binary During 30 days 1
Access-site injury (major) (E) Binary During 30 days 1
Bleeding (major–minor) (E) Ordered During 30 days 3
Number of days hospitalised (E) Discrete During 12 months 2
NYHA functional class (I to IV) (E) Orderedc At 3 months and at 12 months 3
SF-36 Quality of life (E) Continuousc At 3 months and at 12 months 4
Effective orifice area (E) Continuousc At 3 months and at 12 months 4
Prosthesis peak gradient (E) Continuousc At 3 months and at 12 months 4
Prosthesis mean gradient (E) Continuousc At 3 months and at 12 months 4
Prosthesis regurgitation (E) Orderedd At 3 months and at 12 months 3
Prosthesis–patient mismatch (severe) (E) Binary At 3 months and at 12 months 1
Left ventricular ejection fraction (E) Continuousc At 3 months and at 12 months 4
P, primary outcome; E, exploratory outcome; NYHA, New York Heart Association; SF-36, Short-form health survey with 36 questions. aOutcomes defined according
to Valve Academic Research Consortium criteria. bSee analytical procedures under Statistical analysis plan. c Baseline value is measured and is included in the
adjusted analysis. dGraded as none, mild, moderate, or severe.
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must be weighed quantitatively as well as qualitatively.
There was very little experience with TAVI in low-risk
and moderate-risk patients and no randomised trials in-
volving TAVI at the time of the design of this trial dur-
ing 2008/09, so the expected rates of outcome measures
are therefore based on clinical judgement, in-hospital
complication databases, registry data, STS score, and
EuroSCORE. Consequently, there is a degree of uncer-
tainty in estimating the trial sample size as well as calcu-
lating power for the exploratory outcomes.
Of particular concern during and after TAVI is the
possible elevated risk of stroke, unknown durability of
the prosthesis, and the long-term cardiac effect of the
frequent paravalvular leakage and conduction abnormal-
ities. High-risk patients have clinical characteristics (for
example, previous stroke, peripheral vascular disease,
hypertension) that increase the risk of stroke and other
complications with any major cardiovascular interven-
tion. Less morbid patients with a good functional pre-
intervention status are likely to benefit even more from
TAVI than these high-risk patients, and complicationrates are expected to decline. However, no safety data
exist for this particular patient population. The decision
to include this low-risk group of patients in the trial
therefore presents a dilemma, since balancing the risk of
the abovementioned complications and expanding our
knowledge of this new treatment modality is difficult.
The setting of a randomised clinical trial with extensive
follow-up and data safety monitoring seems to justify
the decision. Should the prosthesis used in either group
become dysfunctional, most patients will be candidates
for either re-TAVI (valve-in-valve procedure) or surgical
prosthesis replacement [21,33,34].
Patient eligibility for AV intervention and trial enrol-
ment is evaluated consecutively at a multidisciplinary
conference. In an attempt to explore the effect of TAVI
in AV stenosis most specifically, patients with significant
coronary artery disease requiring revascularisation at the
time of referral are excluded. Study results will conse-
quently not be readily applicable for a large group of AV
stenosis patients requiring concomitant revascularisa-
tion. On the contrary, the study cohort should reflect
patients seen in clinical practice, and therefore patients
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farction are included. Patients with myocardial infarction
and/or percutaneous coronary intervention with a drug-
eluted stent within the previous year are excluded, how-
ever, since discontinuation of dual-antiplatelet therapy
prior to surgery could expose these patients to a
thromboembolic risk. Patients with atrial fibrillation are
also included. To avoid redo-valve procedures due to
expected prosthesis degeneration and mechanical valve
prostheses, we chose the 70-year-old minimum age
criterion.
Patients are excluded if they have undergone previous
open cardiac surgery, since SAVR with re-sternotomy
and mediastinal dissection after pericardiotomy repre-
sents a different and higher risk procedure than first-
time SAVR.
Similar postprocedure antithrombotic therapy in both
treatment groups was chosen to avoid the confounding
effect of different medical antithromboembolic protec-
tion in the two intervention groups. This strategy was
not in accordance with the guidelines at the time of
designing the trial, which recommended 3 months of
oral anticoagulation after SAVR [4]. No evidence existed
for the optimal antithrombotic treatment after TAVI
[35]. This situation has not changed substantially [5].
Only one TAVI system is used in the trial. Most cen-
tres use only one system as the technology is still new
and requires a substantial amount of experience to be
performed safely. However, as experience with more
devices grows, a more complete picture of TAVI and its
effectiveness should be evaluated in randomised trials
comparing surgery with TAVI using all available delivery
systems and prostheses.
We have tried to minimise bias in different ways. Selec-
tion bias is minimised by consecutive enrolment and cen-
tral randomisation ensuring random allocation and
allocation concealment [36,37]. The trial is not blinded
owing to the inherently different nature of the two treat-
ment modalities. Unblinded trials are at risk of introdu-
cing performance, collateral intervention, attrition, and
assessment bias [36,37]. No investigator performs both
interventions, but obvious differences in experience with a
new procedure (TAVI) and a well-established procedure
(SAVR) will introduce performance bias. Investigators per-
forming TAVI have all done more than 75 procedures be-
fore this trial began. All cardiac surgeon investigators have
extensive SAVR experience. The blinding of the event ad-
judication process for the primary outcome will diminish
assessment bias. Publication of the trial protocol prior to
analysing and reporting the data will prevent outcome
reporting bias, and the multicentre design will improve
external validity. The trial budget will unfortunately only
accommodate 10% data monitoring, which obviously pre-
sents a limitation. Members of the independent DMSCand event adjudication committee have not been involved
in any aspects of the trial design or conduct.
Other trials comparing new endovascular treatments
against surgery have demonstrated that the overall benefit
of a new procedure requires weighing of the relative risks
and benefits in specific patient populations. There must
be a reasonable balance between safety, effectiveness, and
device durability. Safety may be more important than sub-
optimal effectiveness and durability for some patients.
This concept demands patient assessment by an interven-
tionalist and a cardiac surgeon before guidance can be
given to the patient. Trials have thus suggested that sur-
gery could perhaps be deferred as first-line treatment for
certain high-operative-risk patients in myocardial revascu-
larisation and mitral valve repair. This suggestion is also
in accordance with patient preferences and wishes toward
less invasive treatment options.
In conclusion, the NOTION trial is designed to com-
pare the safety and effectiveness of TAVI versus conven-
tional SAVR in the treatment of patients 70 years of age
or older with stand-alone severe degenerative AV sten-
osis. TAVI may reduce postoperative morbidity and
mortality without compromising a favourable functional
outcome. This could expand the patient population re-
ferred for AV intervention and change the type of inter-
vention used.
Trial status
Since screening began in December 2009 and up to De-
cember 2012, 269 patients have been enrolled. Enrol-
ment is expected to be complete at the end of January
2013.
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